Search Result

Results for "

Aβ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (54) 5-HT Receptor (2) Acyltransferase (1) Adrenergic Receptor (1) Amino Acid Derivatives (1) Apoptosis (2) Autophagy (1) Bacterial (1) Beta-secretase (9) CaMK (1) Cannabinoid Receptor (1) CDK (1) Cholinesterase (ChE) (20) EGFR (1) Ephrin Receptor (1) Fluorescent Dye (2) G-quadruplex (1) GABA Receptor (1) GSK-3 (2) iGluR (2) Keap1-Nrf2 (2) mGluR (1) Monoamine Oxidase (3) mTOR (1) NF-κB (1) Potassium Channel (1) Prolyl Endopeptidase (PREP) (1) Reactive Oxygen Species (2) ROS Kinase (2) Sigma Receptor (1) Somatostatin Receptor (1) Steroid Sulfatase (1) Tau Protein (2) TMV (1) γ-secretase (8)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (1) Infection (1) Inflammation/Immunology (6) Neurological Disease (87)

By Targets:

Amyloid-β (54)

5-HT Receptor (2)

Acyltransferase (1)

Adrenergic Receptor (1)

Amino Acid Derivatives (1)

Apoptosis (2)

Autophagy (1)

Bacterial (1)

Beta-secretase (9)

CaMK (1)

Cannabinoid Receptor (1)

CDK (1)

Cholinesterase (ChE) (20)

EGFR (1)

Ephrin Receptor (1)

Fluorescent Dye (2)

G-quadruplex (1)

GABA Receptor (1)

GSK-3 (2)

iGluR (2)

Keap1-Nrf2 (2)

mGluR (1)

Monoamine Oxidase (3)

mTOR (1)

NF-κB (1)

Potassium Channel (1)

Prolyl Endopeptidase (PREP) (1)

Reactive Oxygen Species (2)

ROS Kinase (2)

Sigma Receptor (1)

Somatostatin Receptor (1)

Steroid Sulfatase (1)

Tau Protein (2)

TMV (1)

γ-secretase (8)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (6)

Neurological Disease (87)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149583

Aβ-IN-8

Amyloid-β Neurological Disease

Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation .

Aβ-IN-8	Amyloid-β	Neurological Disease
Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation .

HY-149582

Aβ-IN-7	Amyloid-β	Neurological Disease
Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .

HY-150003

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-149246

Aβ-IN-6	Amyloid-β Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research .

HY-P3688

β-Amyloid (1-38)

Aβ (1-38); Aβ38
Amyloid-β Others

β-Amyloid (1-38) (Aβ (1-38); Aβ38) is aAβ Fragment.

β-Amyloid (1-38) Aβ (1-38); Aβ38	Amyloid-β	Others
β-Amyloid (1-38) (Aβ (1-38); Aβ38) is aAβ Fragment.

HY-144326

Aβ-IN-1	Amyloid-β	Neurological Disease
Aβ-IN-1 is a Aβ1–42 aggregation inhibitor. Aβ-IN-1 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-1 can be used for the research of conformational disorders .

HY-144327

Aβ-IN-2	Amyloid-β	Neurological Disease
Aβ-IN-2 is a Aβ1–42 aggregation inhibitor. Aβ-IN-2 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-2 can be used for the research of conformational disorders .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-147980

Aβ-IN-5	Amyloid-β Cholinesterase (ChE)	Neurological Disease
Aβ-IN-5 (Compound e12) is an orally active Aβ aggregation inhibitor. Aβ-IN-5 also inhibits AChE and BuChE with IC₅₀ values of 21.29 μM and 1.32 μM, respectively. Aβ-IN-5 shows excellent neuroprotective effects and low neurotoxicity .

HY-136866

Aβ42-IN-2	γ-secretase	Neurological Disease
Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC₅₀ of 6.5 nM for Αβ₄₂. Aβ42-IN-2 can be used for the research of Alzheimer's disease .

HY-130609

Aβ42-IN-1	γ-secretase	Neurological Disease
Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM). Aβ42-IN-1 potently reduced Aβ42 levels with an IC₅₀ value of 0.091 µM without CYP3A4 inhibition. Aβ42-IN-1 shows a sustained pharmacokinetic profile.

HY-149763

Aβ42 agonist-1	Amyloid-β	Neurological Disease
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-149764

Aβ42 agonist-2	Amyloid-β	Neurological Disease
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-161109

Aβ42-IN-4

Amyloid-β Neurological Disease

Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

Aβ42-IN-4	Amyloid-β	Neurological Disease
Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

HY-161110

Aβ42-IN-5	Amyloid-β	Neurological Disease
Aβ42-IN-5 (Compound 0152) is an oral active amyloid precursor protein (APP) degrader that can reduce Aβ42 in Alzheimer's disease iPSC neurons. Aβ42-IN-5 can bind CAPRIN1 and APP and enhance the protein-protein interaction .

HY-141661

Aβ/tau aggregation-IN-1	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-1 is a potent Aβ_1-42 β-sheets formation and tau aggregation inhibitor. The K_D values of Aβ/tau aggregation-IN-1 with Aβ_1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .

HY-153430

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-130609A

Aβ42-IN-1 free base	γ-secretase	Neurological Disease
Aβ42-IN-1 free base (compound 1v) is an orally active, high brain exposure γ-secretase modulator. Aβ42-IN-1 free base potently reduces Aβ42 levels with an IC₅₀ value of 0.091 µM, and significantly reduces brain Aβ42 levels in mice. Aβ42-IN-1 free base is a promising compound for the treatment of Alzheimer’s disease .

HY-139740

Aβ Fibrillization modulator 1

Amyloid-β Neurological Disease

Aβ Fibrillization modulator 1 stabilizes Aβ monomers.

Aβ Fibrillization modulator 1	Amyloid-β	Neurological Disease
Aβ Fibrillization modulator 1 stabilizes Aβ monomers.

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-162093

Aβ1–42 aggregation inhibitor 2	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of? Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

HY-P0128

β-Amyloid (25-35) Maximum Cited Publications 20 Publications Verification Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-157440

AChE/Aβ-IN-3	Amyloid-β Reactive Oxygen Species Cholinesterase (ChE)	Neurological Disease
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC_50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .

HY-155733

AChE/Aβ-IN-1	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-1 (compound 32) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with an IC₅₀ of 86 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 3.876 μM. AChE/Aβ-IN-1 also inhibits Aβ aggregation and shows good blood-brain barrier permeability and neuroprotection. AChE/Aβ-IN-1 improves cognitive and spatial memory impairment in rats model .

HY-155735

AChE/Aβ-IN-2	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-2 (compound 33) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with IC₅₀ of 135 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 5.054 μM. AChE/Aβ-IN-2 also inhibits Aβ aggregation and shows good blood-brain barrier permeability. AChE/Aβ-IN-2 improves cognitive and spatial memory impairment in rats model .

HY-157441

AChE/Aβ-IN-4	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC₅₀ values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease .

HY-163320

AChE/Aβ-IN-5	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P5906

Citrullinated amyloid-β (1-40) peptide (human) Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-146483

Anti-Aβ agent 1A	Amyloid-β	Neurological Disease Inflammation/Immunology
Anti-Aβ agent 1A (compound M15) has potent activity against amyloid-β. Anti-Aβ agent 1A possesses can significantly inhibit LPS-induced levels of IL-1β, IL-6 and TNF-α, and reduces the apoptosis of SH-SY5Y induced by H₂O₂ through mitochondria pathway. Anti-Aβ agent 1A possesses antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used for researching Alzheimer’s disease (AD) .

HY-144388

ChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ_1-42 aggregation inhibitor with IC₅₀s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ_1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-149272

tau/Aβ40 aggregation-IN-1	Tau Protein Amyloid-β Cholinesterase (ChE)	Neurological Disease
tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ₄₀ aggregation inhibitor with IC₅₀s of 1.8 μM and 1.3 μM, respectively .

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .

HY-107758

Y-29794 oxalate	Prolyl Endopeptidase (PREP)	Cancer
Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the IRS1-AKT-mTORC1 pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) .

HY-101514

β3-AR agonist 1	Adrenergic Receptor	Cardiovascular Disease Endocrinology
β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC₅₀=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold) .

HY-B0949

Protriptyline hydrochloride 3 Publications Verification	Cholinesterase (ChE)	Neurological Disease
Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD.

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-103538

JLK-6	Amyloid-β	Neurological Disease
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .

HY-148913

CS587	CaMK	Neurological Disease
CS587 is a specific inhibitor of CaMK1D with neurocytotoxicity at 10 μM. CS587 modulates the sensitivity of neuronal cells to Aβ oligomer toxicity .

HY-156011

PSEN1-IN-1	γ-secretase	Neurological Disease
PSEN1-IN-1 (Compound (+)-13b) is a PSEN1 inhibitor. PSEN1-IN-1 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC₅₀s of 19 and 5.5 nM. PSEN1-IN-1 can be used for Alzheimer's disease research .

HY-156012

PSEN1-IN-2	γ-secretase	Neurological Disease
PSEN1-IN-2 (Compound 13K) is a PSEN1 inhibitor. PSEN1-IN-2 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC₅₀s of 6.9 and 2.4 nM. PSEN1-IN-2 can be used for Alzheimer's disease research .

HY-162338

BChE-IN-29	Cholinesterase (ChE)	Neurological Disease
BChE-IN-29 (Compound 27a) is a BChE inhibitor (IC₅₀: 0.078 μM and 0.74 μM for BChE and AChE respectively). BChE-IN-29 has anti-inflammatory activity and can be used for research of AD .

HY-109052

Atabecestat JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .

HY-13505

AM281

Cannabinoid Receptor Neurological Disease

AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM .

HY-136736

β-Secretase Inhibitor II	Beta-secretase	Neurological Disease
β-Secretase Inhibitor II is a β-Secretase inhibitor. β-Secretase Inhibitor II is a simple tripeptide aldehyde (IC₅₀=700 nM for inhibition of total Aβ and IC₅₀=2.5 μM for Aβ_1–42). β-Secretase Inhibitor II can be used for the research of Alzheimer's disease .

HY-P3845

(Gly22)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area

HY-P3688

β-Amyloid (1-38)

Aβ (1-38); Aβ38
Amyloid-β Others

β-Amyloid (1-38) (Aβ (1-38); Aβ38) is aAβ Fragment.

HY-P3779

Amyloid 17-42 Aβ(17-42)	Apoptosis	Neurological Disease
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .

HY-P3275

β-Amyloid (17-40) Aβ(17-40)	Amyloid-β	Neurological Disease
β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease .

HY-P5332

Aβ1-14-εK-HBsAg3 Th UB311 immunogen II	Peptides	Others
Aβ1-14-εK-HBsAg3 Th (UB311 immunogen II) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P5333

Aβ1-14-εK-KKK-MvF5 Th UB311 immunogen I	Peptides	Others
Aβ1-14-εK-KKK-MvF5 Th (UB311 immunogen I) is a biological active peptide. (one of UB-311's Aβ1–14–targeting peptides (B-cell epitope))

HY-P0128

β-Amyloid (25-35) 15+ Cited Publications Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P5906

Citrullinated amyloid-β (1-40) peptide (human) Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-P10040

(Gln22)β-Amyloid (1-40) human

Peptides Neurological Disease

(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-P3845

(Gly22)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P5156

BDS-I	Potassium Channel	Neurological Disease
BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-W111226

Fmoc-His(3-Me)-OH	Amyloid-β Amino Acid Derivatives	Cardiovascular Disease
Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC₅₀s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca ²⁺]_i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks